In a surprise move, Shire Pharmaceuticals has ended its bid for FDA approval for its Replagal biologic for treating Fabry disease, a rare, but life-threatening genetic disorder.
The possibility of not only developing AIDS and having a problem, a life-threatening problem, but the problem of developing other life-threatening disease is there every day of their lives.